GeneDx Holdings Corp. Class A Common StockWGS
Scheduled
GeneDx Holdings Corp. Class A Common Stock Canaccord Genuity's 46th Annual Growth Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- GeneDx reported second quarter results with 32% volume growth for pediatric rare disease exome and whole genome sequencing tests.
- The company returned to adjusted profitability about one quarter ahead of expectations.
- Commercial payer coverage for whole genome sequencing increased from 47% to 88% of commercial lives within one quarter, adding 56 million covered lives.
- Despite volume growth, revenue growth lagged due to challenges in monetizing demand, with a reaffirmed revenue guidance of at least $475 million for 2026.
- In the outpatient segment, whole genome sequencing represented 32% of tests in Q2, down from 40% in Q1 but up from 20% a year ago, reflecting a secular shift from exome to genome testing.
- GeneDx launched an exome-to-genome reflex test priced and reimbursed similar to exome to manage the transition between exome and genome.
- Collection rates for genome tests in Q2 were 32%, similar to exome, with roughly one-third of all tests paid by insurance, highlighting revenue cycle inefficiencies.
- The company is investing in payer-specific workflows, process improvements, and AI to address administrative denials and improve collections.
- Recent policy wins include California Medi-Cal genome coverage effective November 2025 and new commercial coverage from a major lab benefit manager, but revenue benefits are expected mainly beyond 2026.
- The American Academy of Pediatrics guideline update in June 2025 endorses exome and genome as first-line diagnostics for children with intellectual developmental delay, with material volume impact expected by Q4 2026.
- The NICU market showed solid growth in H1 2026, with efforts ongoing to increase programmatic ordering across hospital systems.
- GeneDx nearly tripled its commercial team size over the past year and maintains about 80% market share of clinical exome and genome testing in the U.S.
- Turnaround times average 2 to 3 weeks, with ongoing focus on improving customer experience and operational efficiency.
- Mark Gardner was recently appointed president, bringing operational and revenue cycle management expertise to support scaling and process improvements.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring